Replicor to Make Six Presentations at EASL 2015
NEW YORK, April 8, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B (HBV) and hepatitis D (HDV) patients, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted six abstracts for presentation at the EASL 2015 annual meeting to be held April 22-26, 2015 in Vienna, Austria.
Four presentations, one oral and three poster, disclose new clinical and mechanistic data on the activity of nucleic acid polymers (NAPs) against chronic hepatitis B infection:
- HBV RNA dynamics in patients receiving combined REP 2139-Ca / immunotherapy, a retroactive analysis from the REP 102 Asian trial in patients with chronic hepatitis B infection (Abstract O114).
- Serum cytokine dynamics in patients receiving combined REP 2139-Ca / immunotherapy, a retroactive analysis from the REP 102 Asian trial in patients with chronic hepatitis B infection (Abstract P0659).
- Pre-clinical analysis of activity and liver PK of various next generation NAP candidates against HBV infection using the DHBV surrogate model (Abstract P0542).
- Activity of NAP compounds against HBV in vitro in HepaRG cells and primary human hepatocytes (Abstract P0556).
Two late breaking presentations, one oral and one poster, disclose new clinical and mechanistic data on the activity of NAPs against chronic hepatitis B / hepatitis D co-infection:
- Interim disclosure of data from the REP 301 trial assessing the safety and efficacy of REP 2139-Ca alone and in combination with Pegasys® in patients with chronic hepatitis B / hepatitis D co-infection (Abstract LO2).
- Preliminary activity data of NAPs against HDV infection in vitro (Abstract LP26).
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For the 2015 EASL Meeting: https://ilc-congress.eu/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com or follow us on Twitter @replicorinc.